Related Experiment Videos
Erythromycin in treatment of Campylobacter enteritis in children
Insights
Erythromycin ethylsuccinate treatment for Campylobacter enteritis in children significantly reduced bacterial shedding duration compared to no treatment. While diarrhea resolution time remained similar, this antibiotic therapy offers benefits in controlling infection spread.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Campylobacter enteritis is a common cause of diarrhea in infants and children.
- Effective treatment strategies are crucial to reduce symptom duration and transmission.
Purpose of the Study:
- To evaluate the efficacy of erythromycin ethylsuccinate in treating Campylobacter enteritis in pediatric patients.
- To compare treatment outcomes between erythromycin ethylsuccinate therapy and no treatment.
Main Methods:
- A randomized, prospective trial was conducted comparing erythromycin ethylsuccinate (40 mg/kg/day for 7 days) with a no-treatment control group.
- Patient demographics, duration of illness, diarrhea resolution, bacterial shedding, and relapse rates were assessed.
Main Results:
- No significant difference was observed in the mean days to diarrhea resolution between the treatment (3.2 days) and control (3.8 days) groups.
- The mean duration of bacterial shedding was significantly shorter in the erythromycin ethylsuccinate group (2.0 days) compared to the no-treatment group (16.8 days).
- Bacteriologic relapse rates were low in both groups, with one in the treatment group and three in the control group.
Conclusions:
- Erythromycin ethylsuccinate therapy effectively reduces the duration of Campylobacter shedding in children with enteritis.
- While not impacting diarrhea resolution time, the antibiotic may play a role in limiting disease transmission.
Abstract:
Erythromycin ethylsuccinate therapy was compared with no treatment in a randomized, prospective trial of treatment of Campylobacter enteritis in infants and children. Patients received either erythromycin ethylsuccinate (N = 15), 40 mg/kg/day every six hours, for seven days or no treatment (N = 12). The mean age (5.5 v 3.7 years), sex ratio, and mean duration of illness before admission to study (5.5 v 6.4 days) of the two groups were similar. No difference was noted in the mean days to resolution of diarrhea (3.2 v 3.8 days). However, the mean duration of bacterial shedding was shorter in the treatment group (2.0 days) compared with the group without treatment (16.8 days). Bacteriologic relapse occurred in one patient in the treatment group, and three relapses occurred in the group without treatment. Two secondary cases occurred among household contacts, one in each group.